Trestle Biotherapeutics emerges to bioprint implantable kidney tissues
Published in Bioprinting.
The company licensed technology from Prof. Lewis Lab at Harvard’s Wyss Institute
A new company has emerged that is targeting the goal of bioprinting kidney tissue (and eventually kidney organs) for implantation. Trestle Biotherapeutics, a private company based in San Diego, has entered into a license agreement with Harvard University. Under the agreement, Trestle will commercialize a suite of stem cell- and 3D biofabrication-based regenerative medicine technologies developed by Professor Jennifer Lewis Lab at Harvard’s Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), and Brigham and Women’s Hospital.
The core of the technology being licensed to Trestle was developed by a multi-disciplinary research team in the laboratories of Jennifer Lewis, Sc.D. and Ryuji Morizane, M.D., Ph.D. Lewis, whom we had the honor to meet in person when visiting Harvard in 2017, is a Wyss Core Faculty member, leads the Wyss Institute’s 3D Organ Engineering Initiative, is the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard SEAS, and is a Principal Faculty member of the Harvard Stem Cell Institute. Dr. Morizane is a Principal Investigator at Massachusetts General Hospital, an Assistant Professor at Harvard Medical School, an Affiliated Faculty member at Harvard Stem Cell Institute, and a Visiting Scholar at the Wyss Institute. Drs. Lewis and Morizane are both members of Trestle’s scientific advisory board.